Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng

(Length of Conversation: 10 min)

Felix Feng, MD talks with Alicia Morgans, MD, MPH on identifying subsets of patients with prostate cancer that are most responsive to certain therapies so the physician can better individualize treatment options for patients. Topics they discuss include predictive biomarkers, hormone therapy, early initiation of hormone therapy for patients treated with surgery up front.  In addition, they also discussed salvage radiation therapy and the RTOG-9601 study published in the New England Journal of Medicine, where the addition of two years of anti-androgen therapy to salvage radiation improved survival for patients with PSA recurrence after prostatectomy.

Biographies: 
Felix Y. Feng MD, Associate Professor of Radiation Oncology; Urology; and Medicine, Vice Chair for Faculty Development and Director of Translational Research, Department of Radiation Oncology at the University of California of San Francisco

Alicia Morgans, MD, MPH

Read More:
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe